Doe v. Pharmacia & Upjohn, Inc.

122 F. App'x 20
CourtCourt of Appeals for the Fourth Circuit
DecidedFebruary 4, 2005
Docket03-2166
StatusUnpublished
Cited by3 cases

This text of 122 F. App'x 20 (Doe v. Pharmacia & Upjohn, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Doe v. Pharmacia & Upjohn, Inc., 122 F. App'x 20 (4th Cir. 2005).

Opinion

PER CURIAM.

Jane Doe appeals from the dismissal of her amended complaint for failure to state *21 a claim upon which relief can be granted. 1 See Fed.R.Civ.P. 12(b)(6). In her amended complaint, Jane Doe alleges generally that John Doe contracted the human immunodeficiency virus (“HIV”) while he was employed by Pharmacia & Upjohn, Incorporated (“Pharmacia”) as a laboratory technician at Pharmacia’s Montgomery County, Maryland, viral production facility; that Pharmacia negligently tested and informed John Doe that he did not have HIV; and that she subsequently contracted HIV from John Doe through unprotected marital relations. The district court dismissed the amended complaint, which (for our purposes) is grounded in Maryland negligence law, based on its conclusion that Pharmacia did not owe a legal duty of care to Jane Doe.

Pursuant to Maryland Code Ann., Cts. & Jud. Proc. §§ 12-605 and 12-606, we now certify the following questions of Maryland law to the Court of Appeals of Maryland:

(1) For purposes of a negligence cause of action, does a commercial manufacturer of two strains of HIV (“HIV-1” and “HIV-2”), which conducts blood tests on its employees who have been exposed to HIV while on the job, and which manufactures test kits for HIV-1, owe a legal duty to its employees’ spouses to exercise reasonable care in conducting testing, including testing for both strains of the virus?
(2) For purposes of a negligence or negligent misrepresentation cause of action, does a commercial manufacturer of two strains of HIV (“HIV-1” and “HIV-2”), which conducts blood tests of its employees who have been exposed to HIV while on the job, owe a legal duty to its employees’ spouses to exercise reasonable care in informing the employees of the nature of the test results, including the fact that a “false positive” test result for HIV-1 may indicate an HIV-2 infection?

The answers to these questions, which are potentially determinative of this appeal, do not appear to be directly controlled by any Maryland appellate decision, constitutional provision, or statute. We acknowledge that the Court of Appeals of Maryland may reformulate these questions. We also emphasize that these questions are premised on the factual allegations of Jane Doe’s amended complaint which, as explained below, indicate (1) that Pharmacia was specifically aware of many pertinent facts, including the identity of Jane Doe as John Doe’s wife and sexual partner and that the test results could indicate the presence of HIV-2; and (2) that Pharmacia had the capability to test its employees for both HIV-1 and HIV-2.

Counsel of record for Jane Doe is Stephen B. Mercer, Sandler & Mercer, P.C., 27 West Jefferson Street, Suit 201, Rock-ville, Maryland, 20850. Counsel of record for Pharmacia is Stephen E. Marshall, Venable Baetjer and Howard LLP, Two Hopkins Plaza, Suite 1800, Baltimore, Maryland, 21201.

I

Jane Doe alleges the following facts in her amended complaint which, for purposes of this appeal, are not disputed. See GE Inv. Private Placement Partners II v. Parker, 247 F.3d 543, 546 (4th Cir.2001) (“Because the complaint was dismissed pursuant to Rule 12(b)(6), we assume the facts alleged in the complaint are true”).

Jane Doe has been married to, and living as husband and wife with, John Doe since 1971. (Amended Complaint (“A.C.”) H1). Between 1974 and 1991, John Doe *22 was employed by Pharmacia as a laboratory technician at its Montgomery County, Maryland, viral production facility. (A.C., U 4). Pharmacia cultivated pathogens at this facility for use in diagnostic test strips manufactured and sold by Pharmacia and others. (A.C.U 3). John Doe’s primary job responsibilities included the daily feeding, growing, and harvesting of pathogens for large scale propagation. (A.C.11 4). Pharmacia closed this facility in 1991. (A.C.U4).

In 1984, researchers discovered that the primary causative viral agent of acquired immune deficiency syndrome (“AIDS”) is HIV. (A.C.U 7). By 1986, two types of HIV, designated as “HIV-1” and “HIV-2,” had been discovered. (A.C.U 7). The first reported case of HIV-2 in the United States was in 1987, and there have been few reported HIV-2 cases in the United States. (A.C.117). Both HTV-1 and HIV-2 have the same modes of transmission and are associated with AIDS. (A.C.U 7). Compared with persons infected with HIV-1, those with HIV-2 are less infectious early in the course of infection. (A.C.U 7). 2

Beginning in 1984, approximately 80% of the viral production at the Pharmacia facility where John Doe worked was HIV-1 and HIV-2. (A.C. U 3). Pharmacia cultivated and harvested HIV cultures on a daily basis and shipped them to another facility for incorporation into a test for HIV antibodies. (A.C.U 3). Between 1985 and 1991, John Doe was exposed to high concentrations of HIV-1 and HIV-2 while on the job. (A.C.1Í 9).

At some point around 1985, Pharmacia (through its agent) began testing its employees, including John Doe, who were exposed to HIV in the workplace every six months. (A.C.1ÍU 11, 12). Pharmacia manufactured the test strips that were used in this testing. (A.C.U 11). Although Pharmacia was aware of the existence of HIV-2, commercial test kits were not available in the United States to test for an injurious exposure to HIV-2 before 1991 because of the statistically insignificant incidence of the virus. (A.C.1Í 7). Therefore, Pharmacia’s testing was limited to detection of HIV-1. (A.C. U10). However, Pharmacia possessed the materials, knowledge, and capability to manufacture its own test strips to detect HIV-2. (A.C.1110).

The testing conducted by Pharmacia consisted of a two-part protocol whereby an initial screen (the Elisa test) would, if positive, be followed by a confirmatory test (the Western Blot) for HIV-1. (A.C.1111). By 1989, Pharmacia was aware that the HIV tests being used would detect core proteins present in both HIV-1 and HIV-2, and that while the HIV-2 proteins (among other factors) could cause a positive result on the Elisa test, the Western blot test would confirm only the presence of HTV-1. (A.C.U 13). Thus, as of 1989, a person infected with HIV-2 could test positive on the Elisa test but negative on the Western blot test. (A.C.1114). This type of result was considered to be a “false positive” for HIV-1. (A.C.1114).

John Doe consistently tested negative until 1989, when he received a positive result on the Elisa test. (A.C.U1111, 22). John Doe was retested, and the result was negative. (A.C.U22). John Doe’s subsequent tests were negative. (A.C.1122).

Pharmacia did not counsel or warn either John Doe, Jane Doe, or its testing agent about the potential negative ramifications of a “false positive” test. *23 (A.C.H1I15, 16, 18, 19).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Joseph Antonio v. SSA Security, Inc.
749 F.3d 227 (Fourth Circuit, 2014)
Gladys Gardner v. Ally Financial Incorporated
488 F. App'x 709 (Fourth Circuit, 2012)
Doe v. Pharmacia & Upjohn, Inc.
145 F. App'x 823 (Fourth Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
122 F. App'x 20, Counsel Stack Legal Research, https://law.counselstack.com/opinion/doe-v-pharmacia-upjohn-inc-ca4-2005.